BCD-085 clinical trials
Also written BCD-085.
How each study uses BCD-085 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BCD-085
- 7
Studies by the year they started
7 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses BCD-085 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing SpondylitisCompletedPhase 3BiocadNCT03447704Written as BCD-085
- Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic ArthritisCompletedPhase 3BiocadNCT03598751Written as BCD-085
- An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3BiocadNCT03390101Written as BCD-085 Q2W
- Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing SpondylitisCompletedPhase 2BiocadNCT02763111Written as BCD-085
- International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 2BiocadNCT02762994Written as BCD-085
- First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy SubjectsCompletedPhase 1BiocadNCT02380287Written as humanized monoclonal antibody against human IL-17
- Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary CholangitisTerminatedPhase 2BiocadNCT03476993Written as BCD-085